NASDAQ:CLBS - Caladrius Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.60 -0.58 (-9.39 %)
(As of 07/17/2018 05:28 AM ET)
Previous Close$6.18
Today's Range$5.59 - $6.15
52-Week Range$2.63 - $11.65
Volume68,400 shs
Average Volume960,754 shs
Market Capitalization$59.14 million
P/E RatioN/A
Dividend YieldN/A
Beta1.16
Caladrius Biosciences logoCaladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

Receive CLBS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLBS
CUSIPN/A
Phone908-842-0100

Debt

Debt-to-Equity RatioN/A
Current Ratio6.86
Quick Ratio6.86

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.28 million
Price / Sales1.52
Cash FlowN/A
Price / CashN/A
Book Value$5.30 per share
Price / Book1.06

Profitability

EPS (Most Recent Fiscal Year)($1.78)
Net Income$22.97 million
Net MarginsN/A
Return on Equity-39.28%
Return on Assets-30.61%

Miscellaneous

Employees22
Outstanding Shares9,570,000
Market Cap$59.14

The Truth About Cryptocurrencies

Caladrius Biosciences (NASDAQ:CLBS) Frequently Asked Questions

What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences Inc (NASDAQ:CLBS) issued its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($0.80) by $0.28. View Caladrius Biosciences' Earnings History.

When is Caladrius Biosciences' next earnings date?

Caladrius Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Caladrius Biosciences.

What price target have analysts set for CLBS?

2 brokers have issued twelve-month price targets for Caladrius Biosciences' shares. Their forecasts range from $7.00 to $12.00. On average, they anticipate Caladrius Biosciences' share price to reach $9.50 in the next year. This suggests a possible upside of 69.6% from the stock's current price. View Analyst Ratings for Caladrius Biosciences.

What is the consensus analysts' recommendation for Caladrius Biosciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Caladrius Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Caladrius Biosciences' key competitors?

Who are Caladrius Biosciences' key executives?

Caladrius Biosciences' management team includes the folowing people:
  • David J. Mazzo Ph.D., Chief Executive Officer, Independent Director (Age 59)
  • Joseph Talamo, Chief Financial Officer, Senior Vice President (Age 47)
  • Douglas W. Losordo M.D., Chief Medical Officer (Age 58)
  • Gregory B. Brown M.D., Director (Age 64)
  • Richard J. Berman J.D., Independent Director (Age 75)
  • Drew Bernstein CPA., , Independent Director (Age 59)
  • Martyn D. Greenacre, Independent Director (Age 75)
  • Steven Mark Klosk, Independent Director (Age 60)

Has Caladrius Biosciences been receiving favorable news coverage?

News stories about CLBS stock have trended somewhat negative on Tuesday, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Caladrius Biosciences earned a news sentiment score of -0.04 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 43.63 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Caladrius Biosciences?

Shares of CLBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Caladrius Biosciences' stock price today?

One share of CLBS stock can currently be purchased for approximately $5.60.

How big of a company is Caladrius Biosciences?

Caladrius Biosciences has a market capitalization of $59.14 million and generates $35.28 million in revenue each year. The biotechnology company earns $22.97 million in net income (profit) each year or ($1.78) on an earnings per share basis. Caladrius Biosciences employs 22 workers across the globe.

How can I contact Caladrius Biosciences?

Caladrius Biosciences' mailing address is 106 ALLEN ROAD FOURTH FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company can be reached via phone at 908-842-0100 or via email at [email protected]


MarketBeat Community Rating for Caladrius Biosciences (NASDAQ CLBS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  389
MarketBeat's community ratings are surveys of what our community members think about Caladrius Biosciences and other stocks. Vote "Outperform" if you believe CLBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLBS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.